Nöroimmünoloji Pratiğinde Kök Hücre Kullanımı

Canpolat M. Pediatrik Nöroloji Hastalarında Kök Hücre Uygulamaları. In, Temel Pediatrik Nöroloji Tanı ve Tedavi (Kumandaş & Canpolat). Akademisyen Kitabevi, 2022. pp.719-746

Besnek M, Canpolat M. Kök Hücre Tedavisinde: geçmiş, Bugün ve Gelecek. In, Canpolat Çocuk Nörolojisi Pratiğinde Kök Hücre, Multidisipliner Yaklaşım (Editör: Canpolat M). Akademisyen Kitabevi, 2023. pp.395-409)

Kaya MM, Tütün M. KÖK HÜCRE ÜRETİMİ, İZOLASYONU VE TEDAVİDE KULLANIMI.Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni Bulletin of Veterinary Pharmacology and Toxicology

Üstün CA, Dinç GT. Kök Hücre Bilimlerinde Güncel Tanımlar. In, Canpolat Çocuk Nörolojisi Pratiğinde Kök Hücre, Multidisipliner Yaklaşım (Editör: Canpolat M). Akademisyen Kitabevi, 2023. pp.19-30)

Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Research & Therapy. 2019;10.

Mitalipov S, Wolf D. Totipotency, pluripotency and nuclear reprogramming. Adv Biochem Eng Biotechnol. 2009;114:185-99.

Oyar P. DENTAL KÖK HÜCRE KAYNAKLARI VE KEMİK DOKU REJENERASYONUNDA KULLANILMA POTANSİYELLERİ. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi. 2015;25.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76. doi: 10.1016/j.cell.2006.07.024.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts bydefined factors. Cell. 2007 Nov 30;131(5):861-72.doi: 10.1016/j.cell.2007.11.019

Bernemann C, Greber B, Ko K, Sterneckert J, Han D, Araúzo-Bravo M, et al. Distinct Developmental Ground States of Epiblast Stem Cell Linet Determine Different Pluripotency Features. Stem cells (Dayton, Ohio). 2011; 29:1496-503.

Baran M, Kalkan KT. Kök Hücre Çeşitleri ve Kaynakaları. In, Canpolat Çocuk Nörolojisi Pratiğinde Kök Hücre, Multidisipliner Yaklaşım (Editör: Canpolat M). Akademisyen Kitabevi, 2023. Pp.47-56.

Thomson JA I-EJ, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human Blastosists. Science 1145-7.

Barky A, Ali EMM, Mohamed TM. Stem cells, classifications and their clinical applications. Am J Pharmacol Ther. 2017;1(1):001-7.

Birbrair A, Frenette PS. Niche heterogeneity in the bone marrow. Ann N Y Acad Sci. 2016;1370(1):82-96.

Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015;35(2).

Andrzejewska A, Lukomska B, Janowski M. Concise Review: Mesenchymal Stem Cells: From Roots to Boost. Stem Cells. 2019;37(7):855-64.

Gonen Z. B., Şahin N. S. Klinik Kullanım İcin MezenkimalKok Hucrelerin Hazırlanması. Akd Med J.2019; 5(2): 169-175.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The InternationalSociety for Cellular Therapy position statement.Cytotherapy 2006;8:315-17.

Semedo P, Burgos-Silva M, Donizetti-Oliveira C, Camara NOS. How do mesenchymal sem cells repair? Stem Cells in Clinic and Research: IntechOpen; 2011.

Cao W, Cao K, Cao J, Wang Y, Shi Y. Mesenchymal stem cells and adaptive immune responses. Immunology letters. 2015;168(2):147-53.

Liu X, Zhang G, Wei P, Zhong L, Chen Y, Zhang J, et al. Three-dimensional-printed collagen/chitosan/secretome derived from HUCMSCs scaffolds for efficient neural network reconstructi

Clarke DL, Johansson CB, Wilbertz J, Veress B, Nilsson E, Karlström H, et al. Generalized potential of adult neural stem cells. Science. 2000;288(5471):1660-3.

Sharma A, Sane H, Gokulchandran N, Badhe P, Kulkarni P, Pai S, et al. Stem cell therapy in pediatric neurological disabilities. Physical Disabilities-Therapeutic Implications. 2017;117.

Callera F, de Melo CM. Magnetic resonance tracking of magnetically labeled autologous bone marrow CD34+ cells transplanted into the spinal cord via lumbar puncture technique in patients with chronic spinal cord injury: CD34+ cells' migration into the injured site. Stem cells and development. 2007;16(3):461-6.

Torrente Y, Belicchi M, Marchesi C, D'antona G, Cogiamanian F, Pisati F, et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell transplantation. 2007;16(6):563-77.

Rajabzadeh N, Fathi E, Farahzadi R. Stem cell-based regenerative medicine. Stem cell investigation. 2019;6.

Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy. 2016;18(2):160-71.

Konala VBR, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R. The current landscape of the mesenchymal stromal cell secretome: a new paradigm for cell-free regeneration. Cytotherapy. 2016;18(1):13-24.

Lee KH, Tseng WC, Yang CY, Tarng DC. The Anti-Inflammatory, Anti-Oxidative, and Anti-Apoptotic Benefits of Stem Cells in Acute Ischemic Kidney Injury. Int J Mol Sci. 2019;20(14).

Alok Sharma NG, Hemangi Sane, Prerna Badhe. Stem Cell Therapy and Neurorehabilitation In

Pediatric Neurological Disorders. Second ed: Surekha Press; 2015. 207 p.

Fuchs E, Blau HM. Tissue Stem Cells: Architects of Their Niches. Cell Stem Cell. 2020;27(4):532 56.

Verma RS. Breaking dogma for future therapy using stem cell - Where we have reached? Indian J Med Res. 2016;143(2):129-31.

Crisostomo PR, Wang M, Herring CM, Markel TA, Meldrum KK, Lillemoe KD, et al. Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: role of the 55 kDa TNF receptor (TNFR1). Journal of molecular and cellular cardiology. 2007;42(1):142-9.

Markel TA, Crisostomo PR, Wang M, Herring CM, Meldrum DR. Activation of individual tumor necrosis factor receptors differentially affects stem cell growth factor and cytokine production. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2007;293(4):G657-G62.

Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373-83.

Gorabi AM, Kiaie N, Barreto GE, Read MI, Tafti HA, Sahebkar A. The Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in Treatment of Neurodegenerative Diseases. Mol Neurobiol. 2019;56(12):8157-67.

Thomi G, Surbek D, Haesler V, Joerger-Messerli M, Schoeberlein A. Exosomes derived from umbilical cord mesenchymal stem cells reduce microglia-mediated neuroinflammation in perinatal brain injury. Stem Cell Res Ther. 2019;10(1):105.

Soni N, Gupta S, Rawat S, Krishnakumar V, Mohanty S, Banerjee A. MicroRNA-enriched exosomes from different sources of mesenchymal stem cells can differentially modulate functions of immune cells and neurogenesis. Biomedicines. 2021;10(1):69.

Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016;172(1):3-13.

Luca M, Ortega-Castro N, Patti F. Paediatric Multiple Sclerosis: A Scoping Review of Patients' and Parents' Perspectives. Children (Basel). 2021;9(1).

McKay KA, Ernstsson O, Manouchehrinia A, Olsson T, Hillert J. Determinants of quality of life in

Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603-13.

Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet. 2008;9(7):516-26.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86.

Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009;66(8):967-71.

Ghassemi R, Antel SB, Narayanan S, Francis SJ, Bar-Or A, Sadovnick AD, et al. Lesion distribution in children with clinically isolated syndromes. Ann Neurol. 2008;63(3):401-5.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.

Efendi H. MULTİPL SKLEROZ TANI VE TEDAVİ KILAVUZU,2018.

Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz NL. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011;26(6):675-82.

Krysko KM, Graves J, Rensel M, Weinstock-Guttman B, Aaen G, Benson L, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018;91(19):e1778-e87.

Atkins HL, Freedman MS. Five questions answered: a review of autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14(4):888-93.

Nicotera AG, Spoto G, Saia MC, Midiri M, Turriziani L, Amore G, et al. Treatment of multiple sclerosis in children: A brief overview. Clin Immunol. 2022;237:108947.

Simone M, Chitnis T. Use of Disease-Modifying Therapies in Pediatric MS. Curr Treat Options Neurol. 2016;18(8):36.

Das J, Sharrack B, Snowden JA. Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions. Expert Review of Neurotherapeutics. 2020;20(12):1299-313.

Genc B, Bozan HR, Genc S, Genc K. Stem cell therapy for multiple sclerosis. Tissue Engineering and Regenerative Medicine. 2019:145-74.

Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57(8):1217-39.

Cencioni MT, Genchi A, Brittain G, de Silva TI, Sharrack B, Snowden JA, et al. Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party. Front Immunol. 2021;12:813957.

Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55(2):283-306.

Mohty M, Duarte RF, Kuball J, Bader P, Basak GW, Bonini C, et al. Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. Bone Marrow Transplant. 2018;53(12):1548-52.

Sellner J, Rommer PS. Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review. Autoimmun Rev. 2020;19(4):102492.

Openshaw H, Stuve O, Antel JP, Nash R, Lund BT, Weiner LP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 2000;54(11):2147-50.

Cuascut FX, Hutton GJ. Stem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives. Biomedicines. 2019;7(2).

Rice CM, Kemp K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. The Lancet. 2013;382(9899):1204-13.

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. science. 1999;284(5411):143-7.

Venken K, Hellings N, Thewissen M, Somers V, Hensen K, Rummens JL, et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology. 2008;123(1):79-89.

Xin Y, Gao J, Hu R, Li H, Li Q, Han F, et al. Changes of immune parameters of T lymphocytes and macrophages in EAE mice after BM-MSCs transplantation. Immunol Lett. 2020;225:66-73.

Alanazi A, Alassiri M, Jawdat D, Almalik Y. Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis. Regen Ther. 2022;21:201-9.

Ming G-l, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron. 2011;70(4):687-702.

Picard-Riera N, Decker L, Delarasse C, Goude K, Nait-Oumesmar B, Liblau R, et al. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proceedings of the National Academy of Sciences. 2002;99(20):13211-6.

Armstrong RC, Le TQ, Flint NC, Vana AC, Zhou Y-X. Endogenous cell repair of chronic demyelination. Journal of Neuropathology & Experimental Neurology. 2006;65(3):245-56.

Ben‐Hur T, Einstein O, Mizrachi‐Kol R, Ben‐Menachem O, Reinhartz E, Karussis D, et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia. 2003;41(1):73-80.

Shroff G. A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells. Stem Cells Cloning. 2018;11:1-11.

Wang X, Kimbrel EA, Ijichi K, Paul D, Lazorchak AS, Chu J, et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Reports. 2014;3(1):115-30.

Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2022;387(7):631-9.

Thiruvalluvan A, Czepiel M, Kap YA, Mantingh-Otter I, Vainchtein I, Kuipers J, et al. Survival and functionality of human induced pluripotent stem cell-derived oligodendrocytes in a nonhuman primate model for multiple sclerosis. Stem cells translational medicine. 2016;5(11):1550-61.

76 .Zhao T, Zhang ZN, Westenskow PD, Todorova D, Hu Z, Lin T, et al. Humanized Mice Reveal Differential Immunogenicity of Cells Derived from Autologous Induced Pluripotent Stem Cells. Cell Stem Cell. 2015;17(3):353-9.

Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e62.

Tenembaum S, Yeh EA. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front Pediatr. 2020;8:339.

Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature Reviews Neurology. 2019;15(2):89-102.

Fujihara K. MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity–commentary. Multiple Sclerosis Journal. 2020;26(3):276-8.

Fujihara K, Cook LJ. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics. Current Opinion in Neurology. 2020;33(3):300-8.

Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Current opinion in neurology. 2019;32(3):385.

Kitley J, Palace J. Therapeutic options in neuromyelitis optica spectrum disorders. Expert Review of Neurotherapeutics. 2016;16(3):319-29.

Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone marrow transplantation. 2020;55(2):283-306.

Derdelinckx J, Reynders T, Wens I, Cools N, Willekens B. Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD. International Journal of Molecular Sciences. 2021;22(15):7925.

Lu Z, Zhu L, Liu Z, Wu J, Xu Y, Zhang CJ. IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study. Front Neurol. 2020;11:967.

Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-72.

Lewis RA. Chronic inflammatory demyelinating polyneuropathy. Current Opinion in Neurology. 2017;30(5):508-12.

Qin Z, Huang Q, Zou J, Tang L, Hu Z, Tang X. Progress in hematopoietic stem cell transplantation for CIDP. International Journal of Medical Sciences. 2020;17(2):234.

Sureda A, Bader P, Cesaro S, Dreger P, Duarte R, Dufour C, et al. Indications for allo-and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone marrow transplantation. 2015;50(8):1037-56.

Hajj-Ali RA, Calabrese LH. Diagnosis and classification of central nervous system vasculitis. J Autoimmun. 2014;48-49:149-52.

Vera-Lastra O, Sepúlveda-Delgado J, Cruz-Domínguez Mdel P, Medina G, Casarrubias-Ramírez M, Molina-Carrión LE, et al. Primary and secondary central nervous system vasculitis: clinical manifestations, laboratory findings, neuroimaging, and treatment analysis. Clin Rheumatol. 2015;34(4):729-38.

Aviv RI, Benseler SM, Silverman ED, Tyrrell PN, Deveber G, Tsang LM, et al. MR imaging and angiography of primary CNS vasculitis of childhood. AJNR Am J Neuroradiol. 2006;27(1):192-9.

Dabas A, Yadav S. Primary angiitis of the central nervous system: A rare and reversible cause of childhood stroke. J Pediatr Neurosci. 2016;11(4):338-40.

Beelen J, Benseler SM, Dropol A, Ghali B, Twilt M. Strategies for treatment of childhood primary angiitis of the central nervous system. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e567.

Twilt M, Benseler SM. Central nervous system vasculitis in adults and children. Handbook of Clinical Neurology. 2016;133:283-300.

Koluna B Biçen MG Albi G et al* Varıcella zoster central nervous system vasculıtıs after allogeneıc hematopoıetıc stem cell transplant successfully treated with cyclophosphamıde*Published online 2012 (tamamla)

Konen FF,Schwenkenbeche P, Jendretzky F et al.Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications. Cells. 2022 Jul 11;11(14): 2165.doi: 10.3390/cells11142165.